These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

348 related items for PubMed ID: 31127325

  • 41. Real-world vs. randomized trial outcomes in similar populations of rivaroxaban-treated patients with non-valvular atrial fibrillation in ROCKET AF and XANTUS.
    Camm AJ, Amarenco P, Haas S, Hess S, Kirchhof P, Lambelet M, Bach M, Turpie AGG.
    Europace; 2019 Mar 01; 21(3):421-427. PubMed ID: 30052894
    [Abstract] [Full Text] [Related]

  • 42. Effectiveness and Safety of Rivaroxaban 15 or 20 mg Versus Vitamin K Antagonists in Nonvalvular Atrial Fibrillation.
    Blin P, Fauchier L, Dureau-Pournin C, Sacher F, Dallongeville J, Bernard MA, Lassalle R, Droz-Perroteau C, Moore N.
    Stroke; 2019 Sep 01; 50(9):2469-2476. PubMed ID: 31390972
    [Abstract] [Full Text] [Related]

  • 43. A retrospective study of real-world effectiveness and safety of rivaroxaban in patients with non-valvular atrial fibrillation and venous thromboembolism in Saudi Arabia.
    Alosaimi HM, Alqahtani S, Balkhi B, Alqahtani M, Alzamil F, Alhossan A, Alqahtany FS, Alharbi AA, Alqahtani NA, Albackr H, Elgohary G, Algahtani FH.
    PeerJ; 2022 Sep 01; 10():e13974. PubMed ID: 36105646
    [Abstract] [Full Text] [Related]

  • 44. Clinical characteristics and outcomes of Japanese atrial fibrillation patients with poor medication adherence: A sub-analysis of the GENERAL study.
    Akao M, Tsuji H, Kusano K, Matsui K, Hiramitsu S, Hatori Y, Odakura H, Ogawa H.
    J Cardiol; 2023 Feb 01; 81(2):209-214. PubMed ID: 35985869
    [Abstract] [Full Text] [Related]

  • 45. Comparing Stroke and Bleeding with Rivaroxaban and Dabigatran in Atrial Fibrillation: Analysis of the US Medicare Part D Data.
    Hernandez I, Zhang Y.
    Am J Cardiovasc Drugs; 2017 Feb 01; 17(1):37-47. PubMed ID: 27637493
    [Abstract] [Full Text] [Related]

  • 46. Real-world 2-year outcome of atrial fibrillation treatment with dabigatran, apixaban, and rivaroxaban in patients with and without chronic kidney disease.
    Godino C, Melillo F, Rubino F, Arrigoni L, Cappelletti A, Mazzone P, Mattiello P, Della Bella P, Colombo A, Salerno A, Cera M, Margonato A, INSIghT investigators.
    Intern Emerg Med; 2019 Nov 01; 14(8):1259-1270. PubMed ID: 31073827
    [Abstract] [Full Text] [Related]

  • 47. The Comparison of Inappropriate-Low-Doses Use among 4 Direct Oral Anticoagulants in Patients with Atrial Fibrillation: From the Database of a Single-Center Registry.
    Sato T, Aizawa Y, Fuse K, Fujita S, Ikeda Y, Kitazawa H, Takahashi M, Okabe M.
    J Stroke Cerebrovasc Dis; 2018 Nov 01; 27(11):3280-3288. PubMed ID: 30121155
    [Abstract] [Full Text] [Related]

  • 48. Observational study of frailty in older Japanese patients with non-valvular atrial fibrillation receiving anticoagulation therapy.
    Matsui K, Kusano K, Akao M, Tsuji H, Hiramitsu S, Hatori Y, Odakura H, Ogawa H.
    Sci Rep; 2024 Jun 22; 14(1):14423. PubMed ID: 38909144
    [Abstract] [Full Text] [Related]

  • 49. Cost-effectiveness of rivaroxaban versus warfarin in non-valvular atrial fibrillation patients with chronic kidney disease in China.
    Liu L, Hong D, Ma K, Lu X.
    J Clin Pharm Ther; 2021 Jun 22; 46(3):658-668. PubMed ID: 33226144
    [Abstract] [Full Text] [Related]

  • 50. Monitoring of anti-Xa activity and factors related to bleeding events: A study in Japanese patients with nonvalvular atrial fibrillation receiving rivaroxaban.
    Sakaguchi T, Osanai H, Murase Y, Ishii H, Nakashima Y, Asano H, Suzuki S, Takefuji M, Inden Y, Sakai K, Murohara T, Ajioka M.
    J Cardiol; 2017 Sep 22; 70(3):244-249. PubMed ID: 28017463
    [Abstract] [Full Text] [Related]

  • 51. Initiation of rivaroxaban in patients with nonvalvular atrial fibrillation at the primary care level: the Swiss Therapy in Atrial Fibrillation for the Regulation of Coagulation (STAR) Study.
    Engelberger RP, Noll G, Schmidt D, Alatri A, Frei B, Kaiser WE, Kucher N.
    Eur J Intern Med; 2015 Sep 22; 26(7):508-14. PubMed ID: 25935131
    [Abstract] [Full Text] [Related]

  • 52. Comparative safety and effectiveness of dabigatran vs. rivaroxaban and apixaban in patients with non-valvular atrial fibrillation: a retrospective study from a large healthcare system.
    Villines TC, Ahmad A, Petrini M, Tang W, Evans A, Rush T, Thompson D, Oh K, Schwartzman E.
    Eur Heart J Cardiovasc Pharmacother; 2019 Apr 01; 5(2):80-90. PubMed ID: 30500885
    [Abstract] [Full Text] [Related]

  • 53. [Nonvalvular atrial fibrillation: data from the Observatory of Cardiovascular Diseases in the province of Trieste (Italy)].
    Mazzone C, Carriere C, Grande E, Iorio AM, Barbati G, Zecchin M, Serdoz LV, Cioffi G, Tarantini L, Sinagra G, Scardi S, Di Lenarda A.
    G Ital Cardiol (Rome); 2015 Jun 01; 16(6):361-72. PubMed ID: 26156697
    [Abstract] [Full Text] [Related]

  • 54. Has the clinical profile of patients with nonvalvular atrial fibrillation treated with rivaroxaban changed in the last 5 years of use?
    Pimentel Quezada Y, Bonilla Palomas JL, Gámez López AL, Moreno Conde M, López Ibáñez MC, Gallego de la Sacristana López-Serrano Á.
    Future Cardiol; 2018 May 01; 14(3s):47-53. PubMed ID: 29848089
    [Abstract] [Full Text] [Related]

  • 55. Effectiveness and safety of rivaroxaban in a cohort of 142 patients with nonvalvular atrial fibrillation treated with rivaroxaban for the prevention of stroke.
    Cerezo-Manchado JJ, Navarro-Almenzar B, Elvira-Ruiz G, García-Candel F, Flores-Blanco PJ, Caro-Martínez C, Manzano-Fernández S, García-Iniesta N, Sánchez-García J, Cabañas-Perianes V, Moraleda-Jiménez JM.
    Future Cardiol; 2018 May 01; 14(3s):31-37. PubMed ID: 29848091
    [Abstract] [Full Text] [Related]

  • 56. Rivaroxaban in the Prevention of Stroke and Systemic Embolism in Patients with Non-Valvular Atrial Fibrillation: Clinical Implications of the ROCKET AF Trial and Its Subanalyses.
    Spencer RJ, Amerena JV.
    Am J Cardiovasc Drugs; 2015 Dec 01; 15(6):395-401. PubMed ID: 26062914
    [Abstract] [Full Text] [Related]

  • 57. Net clinical benefit of edoxaban versus no treatment in a 'real world' atrial fibrillation population: A modelling analysis based on a nationwide cohort study.
    Blann AD, Banerjee A, Lane DA, Torp-Pedersen C, Lip GY.
    Int J Cardiol; 2015 Dec 15; 201():693-8. PubMed ID: 26379097
    [Abstract] [Full Text] [Related]

  • 58. The predictive ability of the CHADS2 and CHA2DS2-VASc scores for bleeding risk in atrial fibrillation: the MAQI(2) experience.
    Barnes GD, Gu X, Haymart B, Kline-Rogers E, Almany S, Kozlowski J, Besley D, Krol GD, Froehlich JB, Kaatz S.
    Thromb Res; 2014 Aug 15; 134(2):294-9. PubMed ID: 24929840
    [Abstract] [Full Text] [Related]

  • 59. Impact of Modifiable Bleeding Risk Factors on Major Bleeding in Patients With Atrial Fibrillation Anticoagulated With Rivaroxaban.
    Kirchhof P, Haas S, Amarenco P, Hess S, Lambelet M, van Eickels M, Turpie AGG, Camm AJ, XANTUS Investigators*.
    J Am Heart Assoc; 2020 Mar 03; 9(5):e009530. PubMed ID: 32079476
    [Abstract] [Full Text] [Related]

  • 60. Direct comparative effectiveness and safety between non-vitamin K antagonist oral anticoagulants for stroke prevention in nonvalvular atrial fibrillation: a systematic review and meta-analysis of observational studies.
    Li G, Lip GYH, Holbrook A, Chang Y, Larsen TB, Sun X, Tang J, Mbuagbaw L, Witt DM, Crowther M, Thabane L, Levine MAH.
    Eur J Epidemiol; 2019 Feb 03; 34(2):173-190. PubMed ID: 29948370
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 18.